Literature DB >> 18341576

Chinese herbal medicine (Tuhuai extract) exhibits topical anti-proliferative and anti-inflammatory activity in murine disease models.

Mao-Qiang Man1, Yuejun Shi, Mona Man, Seung Hun Lee, Marianne Demerjian, Sandra Chang, Kenneth R Feingold, Peter M Elias.   

Abstract

While psoriasis is one of the most common skin disorders in humans, effective, safe and inexpensive treatments are still largely unavailable. Chinese herbal medicine (CHM) has been used for centuries for treating psoriasis and several reports claim that systemic administration of one such CHM, Tuhuai, mainly composed of flos sophorae, smilax glabra roxb and licorice, is effective in psoriasis. However, the mechanisms by which this CHM improves psoriasis are not yet clear. Two universal features of psoriasis are epidermal hyperplasia and inflammation. Moreover, drugs that specifically inhibit epidermal hyperplasia and/or inflammation are widely used to treat psoriasis. Here, we investigated whether topical applications of Tuhuai extract exhibit anti-proliferative and anti-inflammatory activities in two murine models of inflammatory dermatoses. To assess Tuhuai's potential anti-proliferative effect, we disrupted epidermal barrier function twice-daily for 4 days in normal hairless mice followed by topical applications of either 1% Tuhuai extract or Vehicle to both flanks immediately after each barrier perturbation. Changes in epidermal proliferation and apoptosis were evaluated by immunohistochemistry and TUNEL staining. To assess the anti-inflammatory effects of Tuhuai, both irritant (phorbol ester) and acute allergic contact dermatitis (oxazolone) models were used. Whereas topical Tuhuai extract did not alter epidermal proliferation or induce irritation in normal skin, it both reduced epidermal hyperplasia in the epidermal hyperproliferative model, and reduced inflammation in both irritant and allergic contact dermatitis models. As topical Tuhuai extract exhibits anti-proliferative and anti-inflammatory properties in a variety of human models of inflammatory dermatoses, Tuhuai could provide an effective, relatively safe and inexpensive therapeutic alternative for the treatment of inflammatory dermatoses, including psoriasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18341576      PMCID: PMC2843409          DOI: 10.1111/j.1600-0625.2007.00690.x

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  54 in total

1.  Immunomodulatory activity of the aqueous extract from rhizome of Smilax glabra in the later phase of adjuvant-induced arthritis in rats.

Authors:  Jieyun Jiang; Qiang Xu
Journal:  J Ethnopharmacol       Date:  2003-03       Impact factor: 4.360

2.  Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARalpha activators restores tissue homeostasis.

Authors:  L G Kömüves; K Hanley; M Q Man; P M Elias; M L Williams; K R Feingold
Journal:  J Invest Dermatol       Date:  2000-09       Impact factor: 8.551

3.  Adverse effects with long-term cyclosporin for severe psoriasis.

Authors:  Trevor Markham; A Watson; S Rogers
Journal:  Clin Exp Dermatol       Date:  2002-03       Impact factor: 3.470

4.  Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models.

Authors:  Mary Y Sheu; Ashley J Fowler; Jack Kao; Matthias Schmuth; Kristina Schoonjans; Johan Auwerx; Joachim W Fluhr; Mao-Qiang Man; Peter M Elias; Kenneth R Feingold
Journal:  J Invest Dermatol       Date:  2002-01       Impact factor: 8.551

5.  Astilbin suppresses delayed-type hypersensitivity by inhibiting lymphocyte migration.

Authors:  Yu Cai; Ting Chen; Qiang Xu
Journal:  J Pharm Pharmacol       Date:  2003-05       Impact factor: 3.765

6.  Astilbin suppresses collagen-induced arthritis via the dysfunction of lymphocytes.

Authors:  Y Cai; T Chen; Q Xu
Journal:  Inflamm Res       Date:  2003-08       Impact factor: 4.575

7.  Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density.

Authors:  N J Minaur; D Kounali; S Vedi; J E Compston; J N Beresford; A K Bhalla
Journal:  Rheumatology (Oxford)       Date:  2002-07       Impact factor: 7.580

8.  Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production.

Authors:  Ashley J Fowler; Mary Y Sheu; Matthias Schmuth; Jack Kao; Joachim W Fluhr; Linda Rhein; Jon L Collins; Timothy M Willson; David J Mangelsdorf; Peter M Elias; Kenneth R Feingold
Journal:  J Invest Dermatol       Date:  2003-02       Impact factor: 8.551

9.  Etanercept as monotherapy in patients with psoriasis.

Authors:  Craig L Leonardi; Jerold L Powers; Robert T Matheson; Bernard S Goffe; Ralph Zitnik; Andrea Wang; Alice B Gottlieb
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

10.  The treatment of atopic dermatitis with licorice gel.

Authors:  M Saeedi; K Morteza-Semnani; M-R Ghoreishi
Journal:  J Dermatolog Treat       Date:  2003-09       Impact factor: 3.359

View more
  13 in total

Review 1.  The globalization of traditional medicine in northern peru: from shamanism to molecules.

Authors:  Rainer W Bussmann
Journal:  Evid Based Complement Alternat Med       Date:  2013-12-28       Impact factor: 2.629

2.  Topical hesperidin improves epidermal permeability barrier function and epidermal differentiation in normal murine skin.

Authors:  Maihua Hou; Mona Man; Wenyan Man; Wenyuan Zhu; Melanie Hupe; Kyungho Park; Debra Crumrine; Peter M Elias; Mao-Qiang Man
Journal:  Exp Dermatol       Date:  2012-05       Impact factor: 3.960

3.  Topical apigenin improves epidermal permeability barrier homoeostasis in normal murine skin by divergent mechanisms.

Authors:  Maihua Hou; Richard Sun; Melanie Hupe; Peggy L Kim; Kyungho Park; Debra Crumrine; Tzu-Kai Lin; Juan Luis Santiago; Theodora M Mauro; Peter M Elias; Mao-Qiang Man
Journal:  Exp Dermatol       Date:  2013-03       Impact factor: 3.960

4.  The role of CD44 in cutaneous inflammation.

Authors:  Mona Man; Peter M Elias; Wenyan Man; Yan Wu; Lilly Y W Bourguignon; Kenneth R Feingold; Mao-Qiang Man
Journal:  Exp Dermatol       Date:  2009-03-26       Impact factor: 3.960

5.  Protective Effects of Luteolin on Diabetic Nephropathy in STZ-Induced Diabetic Rats.

Authors:  Guo Guang Wang; Xiao Hua Lu; Wei Li; Xue Zhao; Cui Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2011-04-28       Impact factor: 2.629

6.  Expression of epidermal CAMP changes in parallel with permeability barrier status.

Authors:  Marina Rodriguez-Martin; Gemma Martin-Ezquerra; Mao-Qiang Man; Melanie Hupe; Jong-Kyung Youm; Donald S Mackenzie; Soyun Cho; Carles Trullas; Walter M Holleran; Katherine A Radek; Peter M Elias
Journal:  J Invest Dermatol       Date:  2011-07-28       Impact factor: 8.551

7.  Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis.

Authors:  Li Ye; Chengzhi Lv; George Man; Shunpeng Song; Peter M Elias; Mao-Qiang Man
Journal:  J Invest Dermatol       Date:  2014-04-29       Impact factor: 8.551

8.  Inhibitory Effects of Chemical Compounds Isolated from the Rhizome of Smilax glabra on Nitric Oxide and Tumor Necrosis Factor- α Production in Lipopolysaccharide-Induced RAW264.7 Cell.

Authors:  Chuan-Li Lu; Wei Zhu; Dong-Mei Wang; Wen-Long Chen; Meng-Mei Hu; Min Wang; Xiao-Jie Xu; Chuan-Jian Lu
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-02       Impact factor: 2.629

9.  Topical apigenin alleviates cutaneous inflammation in murine models.

Authors:  Mao-Qiang Man; Melanie Hupe; Richard Sun; George Man; Theodora M Mauro; Peter M Elias
Journal:  Evid Based Complement Alternat Med       Date:  2012-11-19       Impact factor: 2.629

10.  Frequency and pattern of Chinese herbal medicine prescriptions for urticaria in Taiwan during 2009: analysis of the national health insurance database.

Authors:  Pei-Shan Chien; Yu-Fang Tseng; Yao-Chin Hsu; Yu-Kai Lai; Shih-Feng Weng
Journal:  BMC Complement Altern Med       Date:  2013-08-15       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.